Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 12/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5702805 | 1.00 | PREP (0.48) | PREPF2POLBMAOAALDH1A1 | |
| SCHEMBL4581122 | 0.85 | NTMT1 (0.55) | PREPF2 | |
| SCHEMBL5528936 | 0.82 | PREP (0.54) | PREPF2POLBALDH1A1CYP3A4 | |
| SCHEMBL647299 | 0.75 | F2 (0.46) | F2POLBALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL9642111 | 0.74 | MAOA (0.49) | PREPMAOAALDH1A1CYP2C19 | |
| SCHEMBL21430304 | 0.72 | F2 (0.56) | F2POLBALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL380892 | 0.70 | HTT (0.52) | POLBALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL10589601 | 0.70 | HTT (0.52) | POLBALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL13614085 | 0.69 | DPP4 (0.47) | PREPF2POLBCYP3A4CYP2C9 | |
| SCHEMBL10589596 | 0.69 | PREP (0.52) | PREPPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158352-A1 | NOVEL ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | CAN-THERAPY INC. (KR) | 2024-05-16 | — | — | US | disclosed |
| US-9631219-B2 | Metabolic rate indicator for cellular populations | NALCO COMPANY (US) | 2017-04-25 | — | — | US | disclosed |
| US-20150320892-A1 | IMAGING FIBROSIS | GE HEALTHCARE LIMITED (GB) | 2015-11-12 | — | — | US | disclosed |
| EP-2866842-A1 | IMAGING FIBROSIS | GE Healthcare UK Limited (GB) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014001538-A1 | IMAGING FIBROSIS | GE HEALTHCARE LIMITED (GB) | 2014-01-03 | — | — | WO | disclosed |
| WO-2011106363-A2 | METABOLIC RATE INDICATOR FOR CELLULAR POPULATIONS | NALCO COMPANY (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20110207111-A1 | METABOLIC RATE INDICATOR FOR CELLULAR POPULATIONS | ECOLAB USA INC. | 2011-08-25 | — | — | US | disclosed |
| WO-2010072327-A2 | PHARMACEUTICAL COMPOSITION BASED ON PEPTIDE FROM CAMEL MILK | KAMAMED GMBH (DE) | 2010-07-01 | — | — | WO | disclosed |
| EP-1480961-B1 | GLUTAMINYL BASED DPIV INHIBITORS | PROSIDION LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20060287251-A1 | Combination therapy for glycaemic control | DEMUTH HANS-ULRICH | 2006-12-21 | — | — | US | disclosed |
| US-20060194852-A1 | Glutaminyl based DPIV inhibitors | DEMUTH HANS-ULRICH | 2006-08-31 | — | — | US | disclosed |
| EP-1695970-A1 | Peptides useful for competitive modulation of dipeptidyl peptidase IV catalysis | Prosidion Limited (GB) | 2006-08-30 | — | — | EP | disclosed |
| US-7060719-B2 | Glutaminyl based DPIV inhibitors | PROSIDION LIMITED (GB) | 2006-06-13 | — | — | US | disclosed |
| EP-1663200-A2 | COMBINATION THERAPY FOR GLYCAEMIC CONTROL | Prosidion Limited (GB) | 2006-06-07 | — | — | EP | disclosed |
| US-6946480-B2 | Glutaminyl based DPIV inhibitors | PROSIDION LIMITED (GB) | 2005-09-20 | — | — | US | disclosed |
| WO-2005020983-A2 | COMBINATION THERAPY FOR GLYCAEMIC CONTROL | PROSIDION LTD. (GB) | 2005-03-10 | — | — | WO | disclosed |
| EP-1480961-A1 | GLUTAMINYL BASED DPIV INHIBITORS | Prosidion Limited (GB) | 2004-12-01 | — | — | EP | disclosed |
| US-20040167191-A1 | Glutaminyl based DPIV inhibitors | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | US | disclosed |
| WO-2003072556-A1 | GLUTAMINYL BASED DPIV INHIBITORS | PROSIDION LTD. (GB) | 2003-09-04 | — | — | WO | disclosed |
| US-20030162820-A1 | Glutaminyl based DPIV inhibitors | PROSIDION LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194852-A1 | Glutaminyl based DPIV inhibitors | GLS, GLS2, QPCT | PREP 61/4885F2 3578/4885POLB 727/4885 |
| US-20150320892-A1 | IMAGING FIBROSIS | SLC10A1, RHOA, MMP1 | PREP 1245/4885F2 452/4885POLB 4276/4885 |
| US-20040167191-A1 | Glutaminyl based DPIV inhibitors | GLS, SLC7A11, GLS2 | PREP 75/4885F2 4341/4885POLB 913/4885 |
| US-20060287251-A1 | Combination therapy for glycaemic control | IAPP, SLC5A2, GCG | PREP 575/4885F2 1935/4885POLB 1097/4885 |
| US-20030162820-A1 | Glutaminyl based DPIV inhibitors | GLS, SLC7A11, GLS2 | PREP 75/4885F2 4341/4885POLB 913/4885 |
| US-20240158352-A1 | NOVEL ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | DPP4, ADAMTS4, DPP3 | PREP 325/4885F2 4337/4885POLB 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.